Cargando…

HER3 Differentiates Basal From Claudin Type Triple Negative Breast Cancer and Contributes to Drug and Microenvironmental Induced Resistance

Triple Negative Breast Cancer (TNBC) is an aggressive form of Breast Cancer (BC). Numerous kinase inhibitors (KI) targeting different pathway nodes have shown limited benefit in the clinical setting. In this study, we aim to characterize the extent of HER3 reliance and to define the effect of Neureg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinevici, Nicoleta, Ataeinia, Bahar, Zehnder, Veronica, Lin, Kevin, Grove, Lauren, Heidari, Pedram, Mahmood, Umar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715030/ https://www.ncbi.nlm.nih.gov/pubmed/33330026 http://dx.doi.org/10.3389/fonc.2020.554704

Ejemplares similares

Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide
por: de Aguiar Ferreira, Carolina, et al.
Publicado: (2022)

HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells
por: Lyu, Hui, et al.
Publicado: (2023)

High claudin-4 antigen expression in triple-negative breast cancer by the immunohistochemistry method
por: Naimi, Azar, et al.
Publicado: (2022)

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients
por: Dehghani, Mehdi, et al.
Publicado: (2020)

Targeting PVT1 Exon 9 Re-Expresses Claudin 4 Protein and Inhibits Migration by Claudin—Low Triple Negative Breast Cancer Cells
por: Levine, Fayola, et al.
Publicado: (2021)

Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity
por: Ho, Ivy A. W., et al.
Publicado: (2017)

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2021)

Detection of Increased Expression of Claudin-1 in Triple-Negative Breast Cancer: Analysis and Clinical-Pathological Correlation
por: Ouban, Abderrahman, et al.
Publicado: (2023)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021)

Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?
por: Dogra, Atika, et al.
Publicado: (2020)

Newly synthesized claudins but not occludin are added to the basal side of the tight junction
por: Van Itallie, Christina M., et al.
Publicado: (2019)

Differential Expression of Claudin 1 and 4 in Basal Cell Carcinoma of the Skin
por: Nakazawa, T., et al.
Publicado: (2023)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
por: Jääskeläinen, Anniina, et al.
Publicado: (2018)

Twist1 accelerates tumour vasculogenic mimicry by inhibiting Claudin15 expression in triple‐negative breast cancer
por: Zhang, Danfang, et al.
Publicado: (2020)

Microenvironmental contributions to hematopoietic stem cell aging
por: Ho, Ya-Hsuan, et al.
Publicado: (2020)

Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer
por: Umeh-Garcia, Maxine, et al.
Publicado: (2022)

Microenvironmental Targets in Sarcoma
por: Ehnman, Monika, et al.
Publicado: (2015)

Claudin 1 expression in basal-like breast cancer is related to patient age
por: Blanchard, Anne A, et al.
Publicado: (2013)

Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer
por: Kazerouni, Anum S., et al.
Publicado: (2022)

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model
por: Matossian, Margarite D., et al.
Publicado: (2018)

MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer
por: Casciano, Jessica C., et al.
Publicado: (2020)

CYP1B1 Augments the Mesenchymal, Claudin-Low, and Chemoresistant Phenotypes of Triple-Negative Breast Cancer Cells
por: Hollis, Paul R., et al.
Publicado: (2022)

The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge
por: Temian, Daiana Cosmina, et al.
Publicado: (2018)

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2010)

All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4
por: Shousha, Sami, et al.
Publicado: (2019)

Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response
por: Kreike, Bas, et al.
Publicado: (2007)

Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer
por: Umekita, Yoshihisa, et al.
Publicado: (2011)

p16 expression correlates with basal-like triple-negative breast carcinoma
por: Abou-Bakr, Amany A, et al.
Publicado: (2013)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Sung, Vanessa Y. C., et al.
Publicado: (2021)

Microenvironmental Effects on Enzyme Activity
por: Silman, Israel
Publicado: (1969)

Microenvironmental Regulation by Fibrillin-1
por: Sengle, Gerhard, et al.
Publicado: (2012)

Microenvironmental Heterogeneity in Brain Malignancies
por: Perus, Lucas J. M., et al.
Publicado: (2019)

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2011)

The claudins
por: Lal-Nag, Madhu, et al.
Publicado: (2009)

Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells
por: Yi, Huimei, et al.
Publicado: (2020)

Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
por: Alamoodi, Munaser, et al.
Publicado: (2023)

Brachydactyly mental retardation syndrome with growth hormone deficiency
por: Arefzadeh, Alireza, et al.
Publicado: (2018)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_93b9iu02k8dt19spq0ncfqedvh